GlassScriptPhysician profile
Hayden Nix Hemphill
NPI 1396746376
$2,799.18
in general payments reported to CMS, 2019-2025
28 companies · $686 in 2025
The $686 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $134 · 2021: $185 · 2022: $487 · 2023: $394 · 2024: $773 · 2025: $686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,802 · Education: $50.46.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,801.74 |
| Education | $50.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $349.29 | 2019-2025 | Farxiga, Lokelma |
| Calliditas Therapeutics US INC. | $260.69 | 2023-2025 | Tarpeyo |
| Amgen INC. | $227.65 | 2022-2024 | Tavneos, Parsabiv, Aranesp |
| Fresenius USA Marketing, INC. | $217.09 | 2021-2025 | Velphoro, Velphoro |
| Vifor Pharma, INC. | $214.59 | 2021-2023 | Veltassa |
| Ardelyx, INC. | $209.08 | 2024-2025 | Ibsrela |
| Bayer Healthcare Pharmaceuticals INC. | $202.79 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.25 | 2020-2025 | Jardiance |
| Aurinia Pharma U.S., INC. | $113.81 | 2023-2024 | Lupkynis |
| Glaxosmithkline, LLC. | $108.40 | 2022-2025 | Jesduvroq, Benlysta |
| Travere Therapeutics, INC. | $97.16 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $73.52 | 2024-2025 | |
| Ultragenyx Pharmaceutical INC. | $66.83 | 2021-2024 | Crysvita |
| Otsuka America Pharmaceutical, INC. | $61.20 | 2019 | |
| Mallinckrodt Hospital Products INC. | $60.40 | 2022-2023 | Acthar |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $47.32 | 2019 | |
| Akebia Therapeutics INC | $44.34 | 2020-2024 | Auryxia |
| Baxter Healthcare | $38.04 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.38 | 2020 | |
| Novo Nordisk INC | $34.01 | 2025 | Rybelsus, Ozempic |
| Opko Pharmaceuticals, LLC | $31.98 | 2023-2024 | Rayaldee |
| Kyowa Kirin, INC. | $29.28 | 2025 | |
| Alnylam Pharmaceuticals INC. | $25.17 | 2021 | |
| Shire North American Group INC | $20.89 | 2019 | |
| Vantive US Healthcare LLC | $20.62 | 2025 | Renal - Pd |
| Amag Pharmaceuticals, INC. | $16.99 | 2022 | |
| Alexion Pharmaceuticals, INC. | $16.23 | 2020 | |
| Horizon Therapeutics Plc | $14.18 | 2023 | Krystexxa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hayden Hemphill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.